Lilly lifts sales outlook midpoint US$5.5B; shares rise

What happened: a stronger sales outlook, a complicated EPS number

Eli Lilly jumped after its October 29 third-quarter results. Yahoo Finance showed US$1,374.99 at 11:15:38 ET, up $86.69, or 6.73%, from the October 28 close of $1,288.30. These are dated regular-session observations, not live offers or the final daily result. All financial amounts below are U.S. dollars. [1][2]

The saved page recorded 2,132,171 shares traded, against its displayed average volume of 2,495,029. That is 85.46% of an average full day; it is not a time-adjusted measure of unusual volume. The session range at retrieval was $1,330.00–$1,408.38, showing that a strong opening reaction still left room for large swings. [2]

For the quarter ended September 30, revenue reached $24.397 billion, versus $17.601 billion a year earlier. Reported diluted earnings were $7.22 per share, up 16%; adjusted, or non-GAAP, EPS was $7.48, up 7%. Importantly, both current-quarter EPS measures still included $4.57 per share of acquired in-process research and development charges. Adjusted does not mean those charges disappeared. [1]

Why demand and pricing pulled in opposite directions

Lilly attributed the 39% sales increase to 53% volume growth, partly offset by 15% lower realized prices. Those are company-reported growth drivers, not percentages to add mechanically. More treatment demand can expand revenue even while the amount collected per unit falls. [1]

Mounjaro generated $10.723 billion, up 65%, and Zepbound contributed $5.352 billion, up 49%. Together they produced $16.075 billion, a calculated 65.9% of company revenue. That concentration helps explain both the growth opportunity and the sensitivity to reimbursement, pricing and competing diabetes and obesity medicines. [1]

The sales-guidance midpoint increased from $86 billion to $91.5 billion. Yet the adjusted EPS midpoint declined from $36.00 to $35.50: management raised underlying EPS guidance by $4.07, then included $4.57 of third-quarter acquired-research charges. The net change is minus $0.50. This is an accounting bridge, not evidence that all parts of the business weakened. [1]

There is a second qualification. Quarterly revenue included approximately $900 million of benefits, primarily Jardiance milestones and favorable rebate and discount-estimate adjustments. Jardiance milestones contributed $410 million, and Lilly says no further milestones remain. Treating every dollar of this quarter as a repeatable sales run rate would therefore miss an important limitation. [1]

• Demand: Mounjaro and Zepbound were the main growth engines, not an across-the-board price increase. [1]
• Pricing: Lilly cited lower Mounjaro realized prices outside the U.S., primarily from Chinese reimbursement-list inclusion. [1]
• Spending: acquired research can depress current earnings without establishing whether the purchased pipeline will ultimately succeed. [1]

Sector context: a peer checkpoint, not a blanket drug-stock call

Novo Nordisk’s U.S.-listed shares were also higher: $39.04, up $0.75 or 1.96%, at 11:15:29 ET. Its November 4 results for the first nine months of 2026 are the next dated peer checkpoint. Pricing, access and treatment demand deserve comparison; Lilly’s growth does not by itself establish Novo’s future sales or either company’s market share. [4][5]

The macro backdrop is not risk-free either. On October 28, the Federal Reserve held its policy range at 3.75%–4.00%, with two dissenters preferring a quarter-point increase. That provides interest-rate context for equity valuations. The evidence here does not isolate Fed policy as the cause of Lilly’s rally. [6]

What it means for option sellers

Lilly’s earnings release has passed, but that removes only one scheduled information event. OptionCharts displayed 30-day implied volatility of 34.55% and IV rank of 33.74%, dated October 29, when opened at 11:22 ET. Its options are labeled 15-minute delayed. These provider statistics are not executable premiums or a measured post-earnings volatility decline; check live prices before trading. [13]

For the wheel, a cash-secured put means reserving money to buy assigned shares; a later covered call does not erase their downside. A covered call also caps participation in another rally. The decision is about accepting those obligations, not simply collecting a premium after good news. Current spreads, contract terms and live prices still need checking. [8][9][10]

What to watch next

• November 4: Novo Nordisk’s confirmed results date; its call is scheduled for 07:00–08:00 EST. Competitor commentary may change expectations even after Lilly’s own earnings. [5]
• December 9: the decision day of the Fed’s December 8–9 meeting. Longer-dated contracts can span this separate macro event. [7]
• For the next Lilly update: monitor realized pricing and the conversion of treatment demand into sales. No next Lilly earnings date is assumed from an unconfirmed calendar.
• For price monitoring: $1,288.30 is the prior close and $1,330.00–$1,408.38 the saved intraday range, not guaranteed support or resistance. [2]

Photo: Paul Sableman / Wikimedia Commons, CC BY 2.0. This archival February 16, 2011 photograph shows Lilly’s Corporate Center in Indianapolis. It was cropped and resized and does not depict the October 2026 earnings event. Source and license links appear below. [11][12]

Educational market reporting, not personal financial advice. Options can cause substantial losses; hypothetical examples exclude fees and are not trade recommendations.